Welcome to our dedicated page for Lemaitre Vasculr SEC filings (Ticker: LMAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LeMaitre Vascular, Inc. filings document a Nasdaq-listed medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Recent Form 8-K reports furnish quarterly operating and financial results, dividend-related updates, and related press release exhibits.
Proxy and governance filings cover board structure, director elections, executive compensation, advisory say-on-pay matters, and shareholder voting results. The filings also identify the company’s common stock, par value, Nasdaq Global Market listing under LMAT, and related public-company disclosure controls.
LeMaitre Vascular director Joseph P. Pellegrino Jr. reported multiple awards of dividend equivalent rights on derivative securities. On March 26, 2026, he acquired several small grants of Dividend Equivalent Rights, each tied to existing restricted stock unit and performance share unit awards.
Each dividend equivalent right is described as the economic equivalent of one share of LeMaitre Vascular common stock and vests proportionately with the underlying equity awards granted in 2022, 2023, and 2024–2025. These are compensation-related accruals, with no open-market purchases or sales reported in this filing.
LeMaitre Vascular (LMAT) President and Director David B. Roberts reported compensation-related grants of dividend equivalent rights on derivative awards. On March 26, 2026, he acquired multiple small blocks of Dividend Equivalent Rights, each economically equal to one share of common stock and priced at $0.0000 per right.
The footnotes explain these rights accrued on previously granted restricted stock units and performance share units from awards dated December 12, 2022, December 8, 2023, December 6, 2024, February 18, 2025, and December 10, 2025, and vest proportionately with those awards. No open‑market buys or sells were reported; this filing reflects routine equity-based compensation accrual rather than trading activity.
LeMaitre Vascular Senior Vice President of Operations Trent G. Kamke reported seven acquisitions of Dividend Equivalent Rights on March 26, 2026. Each right is economically equivalent to one share of LeMaitre common stock and is tied to previously granted restricted stock unit and performance share unit awards from 2022, 2023, 2024 and 2025, vesting in step with those underlying awards. These entries reflect routine, compensation-related accruals rather than open-market trading.
LeBlanc Dorian Paul reported acquisition or exercise transactions in this Form 4 filing.
LeMaitre Vascular Chief Financial Officer Dorian Paul LeBlanc received additional dividend equivalent rights tied to existing restricted stock unit awards. On March 26, 2026, he was granted 2.0948 dividend equivalent rights related to an RSU award granted on March 10, 2025 and 2.6670 rights related to an RSU award granted on December 10, 2025. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and vests proportionately with the underlying RSUs. Following these awards, his holdings from these grants increased to 11.4217 and 2.6670 dividend equivalent rights, respectively.
LeMaitre Vascular’s Chairman and CEO, George W. LeMaitre, reported routine compensation-related awards rather than market trades. On March 26, 2026, he acquired several blocks of dividend equivalent rights, each economically equal to one share of LeMaitre Vascular common stock.
The rights accrued automatically on earlier restricted stock unit and performance share unit awards granted in December 2022, 2023, and 2024, and they will vest proportionately with those underlying awards. No open-market buying or selling occurred, and the transactions do not change cash holdings.
The Vanguard Group filed Amendment No. 6 to a Schedule 13G/A reporting its holdings in LeMaitre Vascular Inc. The amendment states 0% beneficial ownership and 0 shares beneficially owned as of the filing, following an internal realignment on 01/12/2026 that disaggregated certain subsidiaries' holdings.
The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026. It affirms that no single third party holds more than 5% of the class among accounts aggregated by Vanguard.
LeMaitre Vascular senior vice president Trent G. Kamke exercised stock options and sold the resulting shares. He exercised options for 2,625 shares of common stock at an exercise price of $35.48 per share, then sold 2,625 shares at $108.50 per share, leaving 6,677 shares owned directly.
LeMaitre Vascular’s President and Director David B. Roberts reported an open-market sale of 3,311.68 shares of common stock on March 11, 2026 at a weighted average price of $107.6752 per share. After this transaction, he directly holds 14,667.32 shares of the company’s common stock.
The sale was executed in multiple trades at prices ranging from $106.52 to $108.65, with the weighted average reported. Roberts has undertaken to provide detailed trade and pricing information to the company, its shareholders, or the SEC staff upon request.
LeMaitre Vascular’s Chief Financial Officer Dorian Paul LeBlanc reported routine equity compensation activity. On March 10, 2026, he exercised dividend equivalent rights into 2 shares of common stock at $0.00 per share and now holds 9.3269 dividend equivalent rights. He also holds 2,302 shares of common stock directly after these transactions.
The filing shows 96 shares of common stock were withheld at $109.20 per share to satisfy tax obligations on restricted stock units that vested from an award granted on March 10, 2025. The tax withholding is characterized as an exempt sale under Rule 16b-3(e) and does not reflect an open-market trade.
LMAT files a Form 144 to offer 2,625 shares of Common Stock for sale. The notice states the planned sale arises from a stock option exercise and is dated 03/11/2026.
The filing also records a prior sale of 1,044 shares on 02/27/2026 by Trent G. Kamke for $115,142.76.